Search Results

Displaying Results 1-2 of 2 "'IMCR'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types

Mar 05, 2026, 09:00 ET Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types

Biotechnology (NASDAQ: VIR), Iovance Biotherapeutics (NASDAQ: IOVA), C4 Therapeutics (NASDAQ: CCCC), and Immunocore (NASDAQ: IMCR).

More news about: Equity Insider

Sep 10, 2025, 03:30 ET Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

deals, and driving strategic transactions in pharma and biotech. Previously he served as Vice President, Business Development at Immunocore plc (NASDAQ: IMCR), and led business development and alliance management at Achillion Pharmaceuticals, prior to its acquisition by Alexion Pharmaceuticals (NASDAQ: ALXN)

More news about: Resolution Therapeutics

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.